Deleterious synergistic effects of acute heart failure and diabetes mellitus in patients with acute coronary syndrome: Data from the FAST-MI Registries.

Acute heart failure Acute myocardial infarction Diabetes mellitus Diabète Infarctus aigu du myocarde Insuffisance cardiaque aiguë Long-term outcomes Résultats à long terme

Journal

Archives of cardiovascular diseases
ISSN: 1875-2128
Titre abrégé: Arch Cardiovasc Dis
Pays: Netherlands
ID NLM: 101465655

Informations de publication

Date de publication:
May 2022
Historique:
received: 03 10 2021
revised: 04 02 2022
accepted: 09 02 2022
pubmed: 20 3 2022
medline: 9 6 2022
entrez: 19 3 2022
Statut: ppublish

Résumé

Diabetes mellitus (DM) predisposes patients to acute myocardial infarction (AMI) and acute heart failure (AHF). To assess correlates of AHF occurring at the early stage of AMI and synergism between early AHF and DM on 5-year mortality. FAST-MI 2005 and 2010 included 7839 consecutive patients admitted for AMI. Overall, 2151 patients (27.4%) had a history of diabetes mellitus (DM), of whom 629 (29.2%) were on insulin. Patients with versus without DM were older (mean age: 70.0 vs. 64.7years; P<0.001), with more comorbidities and more severe coronary artery disease. Early AHF (pulmonary oedema or cardiogenic shock) was the most frequent in-hospital complication (12.5%) and was twice as frequent in patients with versus without DM (20.2% vs. 9.6%; adjusted odds ratio: 1.66, 95% confidence interval [CI]: 1.43-1.94; P<0.001). Among in-hospital survivors, patients with DM without AHF and those with AHF without DM had 50% increases in 5-year mortality (adjusted hazard ratio [aHR]: 1.50, 95% CI: 1.32-1.69 and aHR: 1.46, 95% CI: 1.23-1.74; both P<0.001) versus patients without DM or AHF; with the risk among those with DM and AHF being doubled (aHR: 1.97, 95% CI: 1.66-2.34; P<0.0001). Early AHF is the most frequent complication of AMI and is twice as common in patients with versus without DM. After adjustment, early AHF and DM are associated with reduced 5-year survival with synergistic effects in patients with both conditions. https://clinicaltrials.gov (NCT00673036 and NCT01237418).

Sections du résumé

BACKGROUND BACKGROUND
Diabetes mellitus (DM) predisposes patients to acute myocardial infarction (AMI) and acute heart failure (AHF).
AIMS OBJECTIVE
To assess correlates of AHF occurring at the early stage of AMI and synergism between early AHF and DM on 5-year mortality.
METHODS METHODS
FAST-MI 2005 and 2010 included 7839 consecutive patients admitted for AMI.
RESULTS RESULTS
Overall, 2151 patients (27.4%) had a history of diabetes mellitus (DM), of whom 629 (29.2%) were on insulin. Patients with versus without DM were older (mean age: 70.0 vs. 64.7years; P<0.001), with more comorbidities and more severe coronary artery disease. Early AHF (pulmonary oedema or cardiogenic shock) was the most frequent in-hospital complication (12.5%) and was twice as frequent in patients with versus without DM (20.2% vs. 9.6%; adjusted odds ratio: 1.66, 95% confidence interval [CI]: 1.43-1.94; P<0.001). Among in-hospital survivors, patients with DM without AHF and those with AHF without DM had 50% increases in 5-year mortality (adjusted hazard ratio [aHR]: 1.50, 95% CI: 1.32-1.69 and aHR: 1.46, 95% CI: 1.23-1.74; both P<0.001) versus patients without DM or AHF; with the risk among those with DM and AHF being doubled (aHR: 1.97, 95% CI: 1.66-2.34; P<0.0001).
CONCLUSION CONCLUSIONS
Early AHF is the most frequent complication of AMI and is twice as common in patients with versus without DM. After adjustment, early AHF and DM are associated with reduced 5-year survival with synergistic effects in patients with both conditions.
CLINICAL TRIAL REGISTRATION BACKGROUND
https://clinicaltrials.gov (NCT00673036 and NCT01237418).

Identifiants

pubmed: 35304066
pii: S1875-2136(22)00038-9
doi: 10.1016/j.acvd.2022.02.004
pii:
doi:

Banques de données

ClinicalTrials.gov
['NCT01237418', 'NCT00673036']

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

264-275

Informations de copyright

Copyright © 2022 Elsevier Masson SAS. All rights reserved.

Auteurs

Jean-Guillaume Dillinger (JG)

Department of Cardiology, Inserm U942, Lariboisière Hospital, Assistance publique-Hôpitaux de Paris, Université de Paris, 75010 Paris, France.

Guy Achkouty (G)

Department of Cardiology, Inserm U942, Lariboisière Hospital, Assistance publique-Hôpitaux de Paris, Université de Paris, 75010 Paris, France.

Franck Albert (F)

Department of Cardiology, Les Hôpitaux de Chartres, 28630 Le Coudray, France.

Grégoire Muller (G)

Médecine Intensive Réanimation, Centre Hospitalier Régional d'Orléans, 45100 Orléans, France.

Jean-Noël Labèque (JN)

Department of Cardiology, Centre Hospitalier de la Côte Basque, 64100 Bayonne, France.

Louis Moisson (L)

Department of Cardiology, Inserm U942, Lariboisière Hospital, Assistance publique-Hôpitaux de Paris, Université de Paris, 75010 Paris, France.

Jean-François Morelle (JF)

Department of Cardiology, Clinique Saint-Martin, 14000 Caen, France.

Yves Cottin (Y)

Department of Cardiology, University Hospital of Dijon Bourgogne, 21079 Dijon, France.

Theo Pezel (T)

Department of Cardiology, Inserm U942, Lariboisière Hospital, Assistance publique-Hôpitaux de Paris, Université de Paris, 75010 Paris, France.

Pascal Lim (P)

Department of Cardiology, Henri-Mondor University Hospital, Assistance publique-Hôpitaux de Paris, 94000 Créteil, France.

Nadia Aissaoui (N)

Médecine Intensive Reanimation, AP-HP Centre, Hôpital Cochin, Université de Paris, 75014 Paris, France.

François Schiele (F)

Department of Cardiology, Hôpital Jean-Minjoz, Université de Bourgogne-Franche-Comté, 25000 Besançon, France.

Jean Ferrières (J)

Department of Cardiology, Rangueil University Hospital, 31400 Toulouse, France; Department of epidemiology, INSERM UMR 1027, 31000 Toulouse, France.

Denis Angoulvant (D)

Department of Cardiology, CRHU Tours, 37044 Tours, France; EA4245 T2i, Tours University, 37000 Tours, France.

Patrick Henry (P)

Department of Cardiology, Inserm U942, Lariboisière Hospital, Assistance publique-Hôpitaux de Paris, Université de Paris, 75010 Paris, France.

Etienne Puymirat (E)

Department of Cardiology, INSERM U-970, European Hospital of Georges-Pompidou, Assistance publique-Hôpitaux de Paris, Université de Paris, 75015 Paris, France.

Tabassome Simon (T)

Department of Clinical Pharmacology and Clinical Research Platform of East of Paris (URCEST-CRCEST-CRB), Assistance publique-Hôpitaux de Paris, 75011 Paris, France; Sorbonne Université, 75006 Paris, France; Unité INSERM U-1148, FACT, 75018 Paris, France.

Nicolas Danchin (N)

Department of Cardiology, INSERM U-970, European Hospital of Georges-Pompidou, Assistance publique-Hôpitaux de Paris, Université de Paris, 75015 Paris, France. Electronic address: nicolasdanchin@yahoo.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH